1/11/24 17:04 | 1/9/24 | AMLX | Amylyx Pharmaceuticals, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Yeramian Patrick D | MA | O | Chief Me | S | -46 | 16.33 | 0 | -3 | -1 | 206 | D | | | | | | | | | | | | | | |
5/17/23 16:58 | 5/15/23 | AMLX | Amylyx Pharmaceuticals, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Yeramian Patrick D | MA | O | Chief Me | M.d | 68 | 5.68 | 0 | 12 | 6 | 208 | D | | | | | | | | | | | | | | |
5/17/23 16:58 | 5/15/23 | AMLX | Amylyx Pharmaceuticals, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Yeramian Patrick D | MA | O | Chief Me | S.d | -347 | 29.03 | 0 | -12 | -5 | 208 | D | | | | | | | | | | | | | | |
4/19/23 19:45 | 4/17/23 | AMLX | Amylyx Pharmaceuticals, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Yeramian Patrick D | MA | O | Chief Me | M.d | 49 | 0.9895 | 0 | 50 | 31 | 208 | D | | | | | | | | | | | | | | |
4/19/23 19:45 | 4/17/23 | AMLX | Amylyx Pharmaceuticals, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Yeramian Patrick D | MA | O | Chief Me | S.d | -1,514 | 30.54 | 0 | -50 | -19 | 208 | D | | | | | | | | | | | | | | |
3/24/23 18:45 | 3/16/23 | AMLX | Amylyx Pharmaceuticals, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Yeramian Patrick D | MA | O | Chief Me | M.ad | 127 | 2.57 | 0 | 50 | 31 | 208 | D | | | | | | | | | | | | | | |
3/24/23 18:45 | 3/16/23 | AMLX | Amylyx Pharmaceuticals, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Yeramian Patrick D | MA | O | Chief Me | S.ad | -1,741 | 31.87 | 0 | -55 | -21 | 208 | D | | | | | | | | | | | | | | |
3/20/23 20:25 | 3/16/23 | AMLX | Amylyx Pharmaceuticals, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Yeramian Patrick D | MA | O | Chief Me | S.d | -1,741 | 31.87 | 0 | -55 | -26 | 159 | D | | | | | | | | | | | | | | |
1/10/23 19:22 | 1/6/23 | AMLX | Amylyx Pharmaceuticals, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Yeramian Patrick D | MA | O | Chief Me | S | -74 | 36.30 | 0 | -2 | -1 | 204 | D | | | | | | | | | | | | | | |